Approved Indications for Biosimilar Inflectra
In this slideshow, we summarize the approved indications for the rheumatology biosimilar Inflectra (infliximab-dyyb), the boxed warnings and possible side effects.
The U.S. Food and Drug Administration approved Inflectra (infliximab-dyyb) on April 5, 2016 for six indications. Prescribing information from the FDA: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdfÂ
Related Videos
Related Content
